Read More

Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics

Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts on weight and long-term metabolic profile over 52 weeks of treatment.

BMY

Read More

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson’s Disease

Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product quality and infusion device master file. No clinical safety or efficacy issues identified.

SUPN

Read More

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643 demonstrates superior safety and tolerability compared to existing treatments, promising a differentiated solution in the $6.11 billion dry eye disease market.

PTN